FeesSafety
Pluang+

FDA rejects Capricor's Deramiocel for Duchenne muscular dystrophy, citing insufficient effectiveness data

Market News
21 Nov 2026, 02:55 WIB
GlobeNewsWire
View Source
Bearish
FDA rejects Capricor's Deramiocel for Duchenne muscular dystrophy, citing insufficient effectiveness data

Capricor Therapeutics received a Complete Response Letter from the FDA rejecting its Biologics License Application for Deramiocel, a cell therapy for Duchenne muscular dystrophy (DMD). The FDA found the data insufficient to prove the drug's effectiveness and noted clinical deficiencies. Despite two successful clinical trials, Capricor plans to review the FDA's feedback and determine next steps. The company has about $198.5 million in cash to support operations for the next year while it reassesses its strategy.

Capricor Therapeutics' regulatory update on Deramiocel for Duchenne muscular dystrophy provides context for health sector activity. For readers following health stocks, here is Pluang's market snapshot as of Nov 21, 2026 07:41 WIB: out of 150 priced US health-sector stocks, 31 rose and 117 fell. Notable movers include BRKR at USD 56.37 with a 9.23% decline and a typical hold time of 21 days, INO at USD 1.86 up 8.77% with 98% sell order activity and a 41-day hold time, and BFLY at USD 5.35 down 8.55% with a 19-day hold time.

More News

Amazon stock shows no consistent rally after AWS re:Invent conferences, despite strong AWS growth.

Amazon stock shows no consistent rally after AWS re:Invent conferences, despite strong AWS growth.

Amazon's AWS re:Invent conference runs Nov. 30-Dec. 4, but the stock has only outperformed the S&P 500 in 4 of the last 10 post-conference months. AWS sales grew 39% year over year in Q3 2026, driving most of Amazon's profit, yet the stock's price mo...

Market News
Neutral
10 minutes ago
Chipotle and Hershey offer distinct investment appeals: growth vs. profitability heading into 2027.

Chipotle and Hershey offer distinct investment appeals: growth vs. profitability heading into 2027.

Chipotle Mexican Grill focuses on aggressive expansion with over 4,000 restaurants globally and strong digital sales growth, reporting $12.7 billion revenue and $1.4 billion net income in the past year. Hershey, a dominant snack company, posted $12.3...

Market News
Bullish
17 minutes ago
Nvidia shares plunge 14% amid SEC probe and regulatory risks after CEO steps down.

Nvidia shares plunge 14% amid SEC probe and regulatory risks after CEO steps down.

Nvidia's stock dropped 14% following reports that the SEC is investigating the company's accounting practices amid growing regulatory scrutiny. This comes shortly after CEO Jensen Huang stepped down, triggering a 25% loss in share value and a $2.8 tr...

Market News
Bearish
37 minutes ago
Goldman Sachs forecasts S&P 500 to rise 26% to 8,700 by late 2027 amid tech stock value rebound.

Goldman Sachs forecasts S&P 500 to rise 26% to 8,700 by late 2027 amid tech stock value rebound.

Goldman Sachs predicts the S&P 500 will climb about 26% to 8,700 points within the next 12 months, despite recent market volatility and concerns over AI-driven tech investments. The forecast is supported by lower valuations in tech stocks and a forwa...

Bullish
1 hour ago
S&P 500 nearly quadrupled investments in 10 years despite recent pullbacks, driven by rising corporate profits.

S&P 500 nearly quadrupled investments in 10 years despite recent pullbacks, driven by rising corporate profits.

Over the past decade, the S&P 500 index has risen 229%, turning a $1,000 investment into nearly $4,000, mainly due to a 212% increase in corporate earnings rather than valuation changes. Despite recent market drops and volatility, holding through pul...

Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App